 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...192193194195196197198199200201202...235236» |
- ||||| epacadostat (INCB024360) / Incyte
New P1/2 trial, Metastases: A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) (clinicaltrials.gov) - Mar 21, 2017
P1/2, N=332, Not yet recruiting, Sponsor: Incyte Corporation
- Enrollment open, Combination therapy, Metastases: PanCO: A Pilot Study of OncoSil (clinicaltrials.gov) - Mar 21, 2017
P=N/A, N=20, Recruiting, Sponsor: OncoSil Medical Limited
Not yet recruiting --> Recruiting
- || Stivarga (regorafenib) / Bayer
Trial primary completion date, Combination therapy, Metastases: Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 21, 2017
P2, N=181, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2019 --> Nov 2016
- || Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, Combination therapy, Metastases: GP28328: A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 21, 2017
P1, N=240, Active, not recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Feb 2019 --> Nov 2016 Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 20, 2017
P2, N=22, Recruiting, Sponsor: University of Miami
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2017 --> Dec 2019
- | Erbitux (cetuximab) / Eli Lilly
Biomarker, Trial primary completion date, Metastases: POSIBA: Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab (clinicaltrials.gov) - Mar 20, 2017
P2, N=170, Active, not recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Trial primary completion date: Dec 2017 --> Dec 2019 Trial primary completion date: Dec 2016 --> Mar 2017
- | Avastin (bevacizumab) / Roche
Journal: Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. (Pubmed Central) - Mar 17, 2017
P3
Trial registration ClinicalTrials.gov NCT01996306. UMIN000012263.
- ||| ensituximab (NEO-102) / ImmunityBio
Enrollment closed, Trial primary completion date, Metastases: QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer (clinicaltrials.gov) - Mar 17, 2017
P2, N=81, Active, not recruiting, Sponsor: Precision Biologics, Inc
UMIN000012263. Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Mar 2017
- ||| eftozanermin alfa (ABBV-621) / AbbVie, Apogenix
New P1 trial: A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (clinicaltrials.gov) - Mar 16, 2017
P1, N=92, Recruiting, Sponsor: AbbVie
- | Cyramza (ramucirumab) / Eli Lilly
New P2 trial, Metastases: RAMIRIS: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (clinicaltrials.gov) - Mar 16, 2017
P2, N=111, Not yet recruiting, Sponsor: Krankenhaus Nordwest
- | Bavencio (avelumab) / EMD Serono
Enrollment open, Combination therapy, Metastases: Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 (clinicaltrials.gov) - Mar 14, 2017
P2, N=81, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2016 --> Mar 2017 Not yet recruiting --> Recruiting
- ||| Erbitux (cetuximab) / Eli Lilly
Trial completion, Trial primary completion date, Metastases: FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 14, 2017
P1, N=86, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Mar 2017
- || pegilodecakin (LY3500518) / Eli Lilly
Trial primary completion date: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 14, 2017
P1, N=350, Active, not recruiting, Sponsor: ARMO BioSciences
Active, not recruiting --> Completed | Trial primary completion date: Apr 2018 --> Mar 2017 Trial primary completion date: Feb 2017 --> Feb 2018
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial primary completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Mar 14, 2017
P1, N=21, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: Jan 2016 --> Jan 2018
- || Xpovio (selinexor) / Karyopharm
Enrollment closed, Enrollment change, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Mar 14, 2017
P1, N=142, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2016 --> Jan 2018 Recruiting --> Active, not recruiting | N=470 --> 142 | Trial primary completion date: Jun 2018 --> Jun 2019
- | Trial primary completion date: Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 13, 2017
P2, N=35, Recruiting, Sponsor: Sun Yat-sen University
Recruiting --> Active, not recruiting | N=470 --> 142 | Trial primary completion date: Jun 2018 --> Jun 2019 Trial primary completion date: Feb 2018 --> Apr 2017
- | Tomudex (raltitrexed) / Pfizer, AstraZeneca
Enrollment open, Trial initiation date: Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis (clinicaltrials.gov) - Mar 13, 2017
P3, N=360, Recruiting, Sponsor: Zhejiang University
Trial primary completion date: Feb 2018 --> Apr 2017 Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Oct 2015
- | oxaliplatin / Generic mfg., capecitabine / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: IV Ascorbic Acid in Advanced Gastric Cancer (clinicaltrials.gov) - Mar 13, 2017
P3, N=200, Not yet recruiting, Sponsor: Sun Yat-sen University
Not yet recruiting --> Recruiting | Initiation date: May 2015 --> Oct 2015 Trial primary completion date: Jan 2017 --> Dec 2017
- |||| BI 695502 (bevacizumab biosimilar) / Boehringer Ingelheim
Trial primary completion date, Metastases: INVICTAN (clinicaltrials.gov) - Mar 10, 2017
P3, N=120, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Jan 2017 --> Dec 2017 Trial primary completion date: Dec 2017 --> Nov 2018
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Mar 9, 2017
P1b, N=185, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Dec 2017 --> Nov 2018 Trial primary completion date: Apr 2018 --> Apr 2019
- | Avastin (bevacizumab) / Roche
Enrollment change, Metastases: STEAM: Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 9, 2017
P2, N=48, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Apr 2018 --> Apr 2019 N=280 --> 48
- | Enrollment open: Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Mar 9, 2017
P2, N=44, Recruiting, Sponsor: Asan Medical Center
N=280 --> 48 Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: PePiTA: Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer (clinicaltrials.gov) - Mar 8, 2017
P=N/A, N=235, Recruiting, Sponsor: Jules Bordet Institute
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- Phase classification, Combination therapy, Metastases: PanCO: A Pilot Study of OncoSil (clinicaltrials.gov) - Mar 8, 2017
P=N/A, N=20, Not yet recruiting, Sponsor: OncoSil Medical Limited
Trial primary completion date: Dec 2016 --> Dec 2017 Phase classification: P2 --> P=N/A
- | Trial primary completion date, Metastases: FLOT4: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Mar 7, 2017
P2/3, N=716, Active, not recruiting, Sponsor: Krankenhaus Nordwest
Phase classification: P2 --> P=N/A Trial primary completion date: Dec 2016 --> Jun 2017
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Enrollment change, HEOR, Metastases: Impact of Adjuvant FOLFOX on Quality of Life and Sensory Neurotoxicity in Patients With Advanced Gastric Cancer (clinicaltrials.gov) - Mar 7, 2017
P=N/A, N=64, Active, not recruiting, Sponsor: Pontificia Universidad Catolica de Chile
Trial primary completion date: Dec 2016 --> Jun 2017 Recruiting --> Active, not recruiting | N=80 --> 64
- | 5-fluorouracil / Generic mfg.
Trial primary completion date, Metastases: Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer (clinicaltrials.gov) - Mar 6, 2017
P1, N=20, Enrolling by invitation, Sponsor: Virginia Commonwealth University
Recruiting --> Active, not recruiting | N=80 --> 64 Trial primary completion date: Feb 2017 --> Dec 2017
- ||||||| vatalanib (PTK787) / Novartis, Bayer
Trial completion, Metastases: Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 5, 2017
P3, N=855, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2017 --> Dec 2017 No longer recruiting --> Completed
- || Vectibix (panitumumab) / Amgen
Trial primary completion date: PLANET: Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases (clinicaltrials.gov) - Mar 3, 2017
P2, N=80, Completed, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
No longer recruiting --> Completed Trial primary completion date: Aug 2015 --> Mar 2015
- Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
Trial primary completion date, Metastases: PREVIUM: Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab (clinicaltrials.gov) - Mar 3, 2017
P2, N=15, Terminated, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Trial primary completion date: Aug 2015 --> Mar 2015 Trial primary completion date: May 2016 --> Feb 2016
- Xpovio (selinexor) / Karyopharm
Enrollment closed, Trial primary completion date, Metastases: SENTINEL: Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 3, 2017
P1, N=27, Active, not recruiting, Sponsor: GSO Global Clinical Research BV
Trial primary completion date: May 2016 --> Feb 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jun 2017
- | Vectibix (panitumumab) / Amgen
New P2 trial: Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver (clinicaltrials.gov) - Mar 3, 2017
P2, N=80, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Trial primary completion date: CCRe-IV: Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases (clinicaltrials.gov) - Mar 1, 2017
P4, N=336, Recruiting, Sponsor: Hospital Universitari de Bellvitge
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jun 2017 Trial primary completion date: Nov 2016 --> Nov 2017
- | Trial primary completion date: IDEA: Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer (clinicaltrials.gov) - Mar 1, 2017
P3, N=2000, Active, not recruiting, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Trial primary completion date: Nov 2016 --> Nov 2017 Trial primary completion date: May 2016 --> Jun 2017
- | leucovorin calcium / Generic mfg.
Trial completion, Trial primary completion date, Metastases: VELVET: OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 1, 2017
P2, N=49, Completed, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Trial primary completion date: May 2016 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Nov 2014
- ||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Trial primary completion date, HEOR, Metastases: Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen (clinicaltrials.gov) - Mar 1, 2017
P3, N=780, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Nov 2014 Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jan 2017
- | New P3 trial, Metastases: FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer (clinicaltrials.gov) - Feb 28, 2017
P3, N=52, Completed, Sponsor: Yonsei University
- | Avastin (bevacizumab) / Roche
Trial initiation date: IPOXA: Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis (clinicaltrials.gov) - Feb 24, 2017
P1/2, N=47, Not yet recruiting, Sponsor: Hospices Civils de Lyon
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jan 2017 Initiation date: Oct 2016 --> Mar 2017
- | Enrollment closed, Trial primary completion date, Metastases: PRODIGE 35-PANOPTIMOX: First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem (clinicaltrials.gov) - Feb 23, 2017
P2, N=276, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Initiation date: Oct 2016 --> Mar 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017
- | Trial primary completion date: Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer (clinicaltrials.gov) - Feb 23, 2017
P3, N=2000, Active, not recruiting, Sponsor: Hellenic Oncology Research Group
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017 Trial primary completion date: Nov 2016 --> May 2017
- | Arzerra (ofatumumab) / Novartis, Genmab, Rituxan (rituximab) / Roche
Trial primary completion date: Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients (clinicaltrials.gov) - Feb 23, 2017
P2, N=77, Recruiting, Sponsor: Polish Lymphoma Research Group
Trial primary completion date: Nov 2016 --> May 2017 Trial primary completion date: May 2016 --> Oct 2017
- ||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Circulating tumor cells, Tumor cell, Metastases: VISNU-2: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (clinicaltrials.gov) - Feb 23, 2017
P2, N=240, Active, not recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Trial primary completion date: May 2016 --> Oct 2017 Recruiting --> Active, not recruiting
- ||||| Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: VISNU-1: Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells (clinicaltrials.gov) - Feb 23, 2017
P3, N=350, Active, not recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Vectibix (panitumumab) / Amgen
Trial completion, Trial primary completion date: Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques (clinicaltrials.gov) - Feb 23, 2017
P2, N=72, Completed, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jul 2016
- || AZD0156 / AstraZeneca
Trial primary completion date, Combination therapy, Monotherapy, PARP Biomarker, Metastases: AToM: Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (clinicaltrials.gov) - Feb 23, 2017
P1, N=225, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jul 2016 Trial primary completion date: Mar 2019 --> Mar 2020
- | Enrollment closed, Metastases: PRODIGE 37-FIRGEMAX: FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine (clinicaltrials.gov) - Feb 23, 2017
P2, N=127, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial primary completion date: Mar 2019 --> Mar 2020 Recruiting --> Active, not recruiting
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy (clinicaltrials.gov) - Feb 17, 2017
P3, N=2660, Recruiting, Sponsor: Samsung Medical Center
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2017
- || pegilodecakin (LY3500518) / Eli Lilly
Enrollment closed: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Feb 17, 2017
P1, N=350, Active, not recruiting, Sponsor: ARMO BioSciences
Trial primary completion date: Dec 2014 --> Dec 2017 Recruiting --> Active, not recruiting
- conatumumab (AMG 655) / Amgen
Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Feb 15, 2017
P2, N=12, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2017 --> Jul 2017
- ||||||| Tepylute (thiotepa ready to dilute) / Shorla Oncology, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: COG-ACNS0334: Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma (clinicaltrials.gov) - Feb 15, 2017
P3, N=96, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Jan 2017 --> Jul 2017 Active, not recruiting --> Completed